| Name | Title | Contact Details |
|---|
Aoxing Pharmaceutical Company, Inc (NYSE AMEX: AXN) is registered in Florida in US and it is a specialty pharmaceutical company which specializes in research, development, manufacturing and distribution of a variety of narcotics and pain-management products and drug-relief medicine. Aoxing has its office in Jersey city and headquartered in Shijiazhuang City, outside Beijing, Aoxing has the largest and most advanced manufacturing facility for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA). It has strategic alliance partnerships with Johnson Matthey Plc (LSE: JMAT), QRx Pharma (ASX: QRX) and American Oriental Bioengineering, Inc (NYSE: AOB).
All of Ankas programs share the same mission: to eliminate the impact of behavioral health problems for all people.
Find the most effective and affordable therapy, counseling, and treatments with Foresight! With our advanced technology, we make sure to provide the most effective and accurate treatment to our patients. We accept most insurances, so book today and sta...
Developing high-value, global products for patients with significant unmet medical needs in niche indications
Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.